{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:46:15Z","timestamp":1788396375342,"version":"build-2803163510"},"reference-count":126,"publisher":"Hapres","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Geriatr Med Res"],"DOI":"10.20900\/agmr20230004","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T02:35:47Z","timestamp":1683858947000},"source":"Crossref","is-referenced-by-count":3,"title":["Sj\u00f6gren\u2019s Syndrome Treatments in the Microbiome Era"],"prefix":"10.20900","member":"8586","published-online":{"date-parts":[[2023]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/archinte.164.12.1275","article-title":"Clinical manifestations and early diagnosis of Sjogren syndrome","volume":"164","author":"SS","year":"2004","unstructured":"1. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med. 2004;164:1275-84.","journal-title":"Arch Intern Med"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10238-021-00728-6","article-title":"Sj\u00f6gren\u02bcs syndrome: a systemic autoimmune disease","volume":"22","author":"Negrini","year":"2022","unstructured":"2. Negrini S, Emmi G, Greco M, Borro M, Sardanelli F, Murdaca G, et al. Sj\u00f6gren\u02bcs syndrome: a systemic autoimmune disease. Clin Exp Med. 2022;22:9-25.","journal-title":"Clin Exp Med"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjogren's syndrome. Autoimmun Rev. 2010;9:A305-10.","DOI":"10.1016\/j.autrev.2009.11.004"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MD.0b013e31824125e4","article-title":"Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren syndrome","volume":"91","author":"Voulgarelis","year":"2012","unstructured":"4. Voulgarelis M, Ziakas PD, Papageorgiou A, Baimpa E, Tzioufas AG, Moutsopoulos HM. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren syndrome. Medicine. 2012;91:1-9.","journal-title":"Medicine"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1136\/annrheumdis-2012-202863","article-title":"Health-related utility values of patients with primary Sj\u00f6gren's syndrome and its predictors","volume":"73","author":"Lendrem","year":"2014","unstructured":"5. Lendrem D, Mitchell S, McMeekin P, Bowman S, Price E, Pease CT, et al. Health-related utility values of patients with primary Sj\u00f6gren's syndrome and its predictors. Ann Rheum Dis. 2014;73:1362-8.","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Kollert F, Fisher BA. Equal rights in autoimmunity: is Sj\u00f6gren's syndrome ever 'secondary'? Rheumatology (Oxford). 2020;59:1218-25.","DOI":"10.1093\/rheumatology\/keaa009"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Mavragani CP, Moutsopoulos HM. Primary versus Secondary Sj\u00f6gren Syndrome: Is It Time To Reconsider These Terms? J Rheumatol. 2019;46:665-6.","DOI":"10.3899\/jrheum.180392"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/acr.24597","article-title":"Antibodies to Both Ro52 and Ro60 for Identifying Sj\u00f6gren's Syndrome Patients Best Suited for Clinical Trials of Disease-Modifying Therapies","volume":"74","author":"Arma\u011fan","year":"2022","unstructured":"8. Arma\u011fan B, Robinson SA, Bazoberry A, Perin J, Grader-Beck T, Akpek EK, et al. Antibodies to Both Ro52 and Ro60 for Identifying Sj\u00f6gren's Syndrome Patients Best Suited for Clinical Trials of Disease-Modifying Therapies. Arthritis Care Res (Hoboken). 2022;74:1559-65.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/joim.12992","article-title":"Weight of salivary gland ultrasonography compared to other items of the 2016 ACR\/EULAR classification criteria for Primary Sj\u00f6gren\u02bcs syndrome","volume":"287","author":"Jousse-Joulin","year":"2020","unstructured":"9. Jousse-Joulin S, Gatineau F, Baldini C, Baer A, Barone F, Bootsma H, et al. Weight of salivary gland ultrasonography compared to other items of the 2016 ACR\/EULAR classification criteria for Primary Sj\u00f6gren\u02bcs syndrome. J Intern Med. 2020;287:180-8.","journal-title":"J Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1136\/annrheumdis-2014-205375","article-title":"Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, Zhong R: Epidemiology of primary Sj\u00f6gren's syndrome: a systematic review and meta-analysis","volume":"74","author":"10","year":"2015","unstructured":"10. Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, Zhong R: Epidemiology of primary Sj\u00f6gren's syndrome: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74:1983-1989.","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Cornec D, Chiche L. Is primary Sj\u00f6gren's syndrome an orphan disease? A critical appraisal of prevalence studies in Europe. Ann Rheum Dis. 2015;74:e25.","DOI":"10.1136\/annrheumdis-2014-206860"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1002\/art.39214","article-title":"Prediction of Sj\u00f6gren's Syndrome Years Before Diagnosis and Identification of Patients With Early Onset and Severe Disease Course by Autoantibody Profiling","volume":"67","author":"Theander","year":"2015","unstructured":"12. Theander E, Jonsson R, Sj\u00f6str\u00f6m B, Brokstad K, Olsson P, Henriksson G. Prediction of Sj\u00f6gren's Syndrome Years Before Diagnosis and Identification of Patients With Early Onset and Severe Disease Course by Autoantibody Profiling. Arthritis Rheumatol. 2015;67:2427-36.","journal-title":"Arthritis Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1136\/ard.56.9.521","article-title":"Prevalence of Sj\u00f6gren's syndrome in a closed rural community","volume":"56","author":"Dafni","year":"1997","unstructured":"13. Dafni UG, Tzioufas AG, Staikos P, Skopouli FN, Moutsopoulos HM. Prevalence of Sj\u00f6gren's syndrome in a closed rural community. Ann Rheum Dis. 1997;56:521-5.","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/030097400750001761","article-title":"Health-related quality of life in primary Sj\u00f6gren's syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36","volume":"29","author":"Str\u00f6mbeck","year":"2000","unstructured":"14. Str\u00f6mbeck B, Ekdahl C, Manthorpe R, Wikstr\u00f6m I, Jacobsson L. Health-related quality of life in primary Sj\u00f6gren's syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36. Scand J Rheumatol. 2000;29:20-8.","journal-title":"Scand J Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"10969","DOI":"10.3390\/ijerph191710969","article-title":"Illness Experience and Quality of Life in Sj\u00f6gren Syndrome Patients","volume":"19","author":"Rojas-Alcayaga","year":"2022","unstructured":"15. Rojas-Alcayaga G, Herrera A, Espinoza I, Rios-Erazo M, Aguilar J, Leiva L, et al. Illness Experience and Quality of Life in Sj\u00f6gren Syndrome Patients. Int J Environ Res Public Health. 2022;19:10969.","journal-title":"Int J Environ Res Public Health"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1093\/rheumatology\/keab364","article-title":"Mortality in patients with primary Sj\u00f6gren's syndrome: a systematic review and meta-analysis","volume":"60","author":"Huang","year":"2021","unstructured":"16. Huang H, Xie W, Geng Y, Fan Y, Zhang Z. Mortality in patients with primary Sj\u00f6gren's syndrome: a systematic review and meta-analysis. Rheumatology (Oxford). 2021;60:4029-38.","journal-title":"Rheumatology (Oxford)"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.clim.2017.04.003","article-title":"Innate immunity in Sj\u00f6gren's syndrome","volume":"182","author":"Kiripolsky","year":"2017","unstructured":"17. Kiripolsky J, McCabe LG, Kramer JM. Innate immunity in Sj\u00f6gren's syndrome. Clin Immunol. 2017;182:4-13","journal-title":"Clin Immunol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1586\/1744666X.2014.891439","article-title":"Kroese FG, Abdulahad WH, Haacke E, Bos NA, Vissink A, Bootsma H: B-cell hyperactivity in primary Sj\u00f6gren's syndrome","volume":"10","author":"18","year":"2014","unstructured":"18. Kroese FG, Abdulahad WH, Haacke E, Bos NA, Vissink A, Bootsma H: B-cell hyperactivity in primary Sj\u00f6gren's syndrome. Expert Rev Clin Immunol. 2014;10:483-99.","journal-title":"Expert Rev Clin Immunol"},{"key":"ref18","unstructured":"19. Strand V, Talal N. Advances in the diagnosis and concept of Sj\u00f6gren's syndrome (autoimmune exocrinopathy). Bull Rheum Dis. 1979;30:1046-52."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jdsr.2019.09.006","article-title":"B cell dysregulation in primary Sj\u00f6gren\u02bcs syndrome: A review","volume":"55","author":"Ibrahem","year":"2019","unstructured":"20. Ibrahem HM. B cell dysregulation in primary Sj\u00f6gren\u02bcs syndrome: A review. Jpn Dent Sci Rev. 2019;55:139-44.","journal-title":"Jpn Dent Sci Rev"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.3390\/biom10111539","article-title":"T Cells Subsets in the Immunopathology and Treatment of Sjogren's Syndrome","volume":"10","author":"R\u00edos-R\u00edos","year":"2020","unstructured":"21. R\u00edos-R\u00edos WJ, Sosa-Luis SA, Torres-Aguilar H. T Cells Subsets in the Immunopathology and Treatment of Sjogren's Syndrome. Biomolecules. 2020;10:1539.","journal-title":"Biomolecules"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Dupr\u00e9 A, Pascaud J, Rivi\u00e8re E, Paoletti A, Ly B, Mingueneau M, et al. Association between T follicular helper cells and T peripheral helper cells with B-cell biomarkers and disease activity in primary Sj\u00f6gren syndrome. RMD Open. 2021;7:e001442.","DOI":"10.1136\/rmdopen-2020-001442"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1093\/rheumatology\/kez004","article-title":"T cells in primary Sj\u00f6gren's syndrome: targets for early intervention","volume":"60","author":"Verstappen","year":"2019","unstructured":"23. Verstappen GM, Kroese FGM, Bootsma H. T cells in primary Sj\u00f6gren's syndrome: targets for early intervention. Rheumatology (Oxford). 2019;60:3088-98.","journal-title":"Rheumatology (Oxford)"},{"key":"ref23","unstructured":"24. Bombardieri M, Argyropoulou OD, Ferro F, Coleby R, Pontarini E, Governato G, et al. One year in review 2020: pathogenesis of primary Sj\u00f6gren's syndrome. Clin Exp Rheumatol. 2020;38(Suppl 126):3-9."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"5928232","DOI":"10.1155\/2021\/5928232","article-title":"Advances in Pathogenesis of Sj\u00f6gren's Syndrome","volume":"2021","author":"Tian","year":"2021","unstructured":"25. Tian Y, Yang H, Liu N, Li Y, Chen J. Advances in Pathogenesis of Sj\u00f6gren's Syndrome. J Immunol Res. 2021;2021:5928232.","journal-title":"J Immunol Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/gutjnl-2021-326789","article-title":"Gut microbiome and health: mechanistic insights","volume":"71","author":"de Vos","year":"2022","unstructured":"26. de Vos WM, Tilg H, Van Hul M, Cani PD. Gut microbiome and health: mechanistic insights. Gut. 2022;71:1020-32.","journal-title":"Gut"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41579-020-0433-9","article-title":"Gut microbiota in human metabolic health and disease","volume":"19","author":"Fan","year":"2021","unstructured":"27. Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021;19:55-71.","journal-title":"Nat Rev Microbiol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nature13047","article-title":"A committed precursor to innate lymphoid cells","volume":"508","author":"Constantinides","year":"2014","unstructured":"28. Constantinides MG, McDonald BD, Verhoef PA, Bendelac A. A committed precursor to innate lymphoid cells. Nature. 2014;508:397-401.","journal-title":"Nature"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nri2448","article-title":"Exploring the full spectrum of macrophage activation","volume":"8","author":"DM","year":"2008","unstructured":"29. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958-69.","journal-title":"Nat Rev Immunol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41422-020-0332-7","article-title":"Interaction between microbiota and immunity in health and disease","volume":"30","author":"Zheng","year":"2020","unstructured":"30. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30:492-506.","journal-title":"Cell Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1078\/0171-2985-00094","article-title":"Dendritic cells shuttle microbes across gut epithelial monolayers","volume":"204","author":"Rescigno","year":"2001","unstructured":"31. Rescigno M, Rotta G, Valzasina B, Ricciardi-Castagnoli P. Dendritic cells shuttle microbes across gut epithelial monolayers. Immunobiology. 2001;204:572-81.","journal-title":"Immunobiology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.intimp.2016.02.007","article-title":"Tissue-resident dendritic cells and diseases involving dendritic cell malfunction","volume":"34","author":"Chen","year":"2016","unstructured":"32. Chen K, Wang JM, Yuan R, Yi X, Li L, Gong W, et al. Tissue-resident dendritic cells and diseases involving dendritic cell malfunction. Int Immunopharmacol. 2016;34:1-15.","journal-title":"Int Immunopharmacol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.immuni.2014.05.016","article-title":"Foxp3(+) T cells regulate immunoglobulin a selection and facilitate diversification of bacterial species responsible for immune homeostasis","volume":"41","author":"Kawamoto","year":"2014","unstructured":"33. Kawamoto S, Maruya M, Kato LM, Suda W, Atarashi K, Doi Y, Tsutsui Y, Qin H, Honda K, Okada T, et al. Foxp3(+) T cells regulate immunoglobulin a selection and facilitate diversification of bacterial species responsible for immune homeostasis. Immunity. 2014;41:152-65.","journal-title":"Immunity"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.chom.2007.09.013","article-title":"IgA response to symbiotic bacteria as a mediator of gut homeostasis","volume":"2","author":"Peterson","year":"2007","unstructured":"34. Peterson DA, McNulty NP, Guruge JL, Gordon JI. IgA response to symbiotic bacteria as a mediator of gut homeostasis. Cell Host Microbe. 2007;2:328-39.","journal-title":"Cell Host Microbe"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nature12726","article-title":"Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation","volume":"504","author":"Arpaia","year":"2013","unstructured":"35. Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504:451-5.","journal-title":"Nature"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1126\/science.1241165","article-title":"The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis","volume":"341","author":"Smith","year":"2013","unstructured":"36. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341:569-73.","journal-title":"Science"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1126\/science.1217718","article-title":"The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut","volume":"336","author":"Kawamoto","year":"2012","unstructured":"37. Kawamoto S, Tran TH, Maruya M, Suzuki K, Doi Y, Tsutsui Y, et al. The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut. Science. 2012;336:485-9.","journal-title":"Science"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.immuni.2014.10.010","article-title":"ATP-gated ionotropic P2X7 receptor controls follicular T helper cell numbers in Peyer\u02bcs patches to promote host-microbiota mutualism","volume":"41","author":"Proietti","year":"2014","unstructured":"38. Proietti M, Cornacchione V, Rezzonico Jost T, Romagnani A, Faliti CE, Perruzza L, et al. ATP-gated ionotropic P2X7 receptor controls follicular T helper cell numbers in Peyer\u02bcs patches to promote host-microbiota mutualism. Immunity. 2014;41:789-801.","journal-title":"Immunity"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.immuni.2014.10.004","article-title":"T follicular helper cell differentiation, function, and roles in disease","volume":"41","author":"Crotty","year":"2014","unstructured":"39. Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity. 2014;41:529-42.","journal-title":"Immunity"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1053\/j.gastro.2020.09.056","article-title":"Inflammatory Bowel Diseases (IBD) and the Microbiome-Searching the Crime Scene for Clues","volume":"160","author":"Lee","year":"2021","unstructured":"40. Lee M, Chang EB. Inflammatory Bowel Diseases (IBD) and the Microbiome-Searching the Crime Scene for Clues. Gastroenterology. 2021;160:524-37.","journal-title":"Gastroenterology"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.3390\/nu11102403","article-title":"Celiac Disease and the Microbiome","volume":"11","author":"Valitutti","year":"2019","unstructured":"41. Valitutti F, Cucchiara S, Fasano A. Celiac Disease and the Microbiome. Nutrients. 2019;11:2403.","journal-title":"Nutrients"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1007165","DOI":"10.3389\/fimmu.2022.1007165","article-title":"Gut microbiota and rheumatoid arthritis: From pathogenesis to novel therapeutic opportunities","volume":"13","author":"Zhao","year":"2022","unstructured":"42. Zhao T, Wei Y, Zhu Y, Xie Z, Hai Q, Li Z, et al. Gut microbiota and rheumatoid arthritis: From pathogenesis to novel therapeutic opportunities. Front Immunol. 2022;13:1007165.","journal-title":"Front Immunol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/CM9.0000000000000696","article-title":"Gut microbiota and metabolic syndrome","volume":"133","author":"Wang","year":"2020","unstructured":"43. Wang PX, Deng XR, Zhang CH, Yuan HJ. Gut microbiota and metabolic syndrome. Chin Med J (Engl). 2020;133:808-16.","journal-title":"Chin Med J (Engl)"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1007\/s12264-021-00730-8","article-title":"The Relationship Between the Gut Microbiome and Neurodegenerative Diseases","volume":"37","author":"Zhu","year":"2021","unstructured":"44. Zhu X, Li B, Lou P, Dai T, Chen Y, Zhuge A, et al. The Relationship Between the Gut Microbiome and Neurodegenerative Diseases. Neurosci Bull. 2021;37:1510-1522.","journal-title":"Neurosci Bull"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"622064","DOI":"10.3389\/fimmu.2021.622064","article-title":"New Insights Into the Cancer-Microbiome-Immune Axis: Decrypting a Decade of Discoveries","volume":"12","author":"Jain","year":"2021","unstructured":"45. Jain T, Sharma P, Are AC, Vickers SM, Dudeja V. New Insights Into the Cancer-Microbiome-Immune Axis: Decrypting a Decade of Discoveries. Front Immunol. 2021;12:622064.","journal-title":"Front Immunol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"918619","DOI":"10.3389\/fimmu.2022.918619","article-title":"A Glimpse Into the Microbiome of Sj\u00f6gren's Syndrome","volume":"13","author":"Deng","year":"2022","unstructured":"46. Deng C, Xiao Q, Fei Y. A Glimpse Into the Microbiome of Sj\u00f6gren's Syndrome. Front Immunol. 2022;13:918619.","journal-title":"Front Immunol"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"47. Moon J, Choi SH, Yoon CH, Kim MK. Gut dysbiosis is prevailing in Sj\u00f6gren's syndrome and is related to dry eye severity. PLoS One. 2020;15:e0229029.","DOI":"10.1371\/journal.pone.0229029"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"111352","DOI":"10.1016\/j.celrep.2022.111352","article-title":"Wang X, Pang K, Wang J, Zhang B, Liu Z, Lu S, et al: Microbiota dysbiosis in primary Sj\u00f6gren's syndrome and the ameliorative effect of hydroxychloroquine","volume":"40","author":"48","year":"2022","unstructured":"48. Wang X, Pang K, Wang J, Zhang B, Liu Z, Lu S, et al: Microbiota dysbiosis in primary Sj\u00f6gren's syndrome and the ameliorative effect of hydroxychloroquine. Cell Rep. 2022;40:111352.","journal-title":"Cell Rep"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"852918","DOI":"10.3389\/fmed.2022.852918","article-title":"Gut Microbiota From Sj\u00f6gren syndrome Patients Causes Decreased T Regulatory Cells in the Lymphoid Organs and Desiccation-Induced Corneal Barrier Disruption in Mice","volume":"9","author":"Schaefer","year":"2022","unstructured":"49. Schaefer L, Trujillo-Vargas CM, Midani FS, Pflugfelder SC, Britton RA, de Paiva CS. Gut Microbiota From Sj\u00f6gren syndrome Patients Causes Decreased T Regulatory Cells in the Lymphoid Organs and Desiccation-Induced Corneal Barrier Disruption in Mice. Front Med (Lausanne). 2022;9:852918.","journal-title":"Front Med (Lausanne)"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12934-020-01348-7","article-title":"Gut microbial dysbiosis in individuals with Sj\u00f6gren's syndrome","volume":"19","author":"Mendez","year":"2020","unstructured":"50. Mendez R, Watane A, Farhangi M, Cavuoto KM, Leith T, Budree S,et al. Gut microbial dysbiosis in individuals with Sj\u00f6gren's syndrome. Microb Cell Fact. 2020;19:90.","journal-title":"Microb Cell Fact"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13075-017-1446-2","article-title":"Severe intestinal dysbiosis is prevalent in primary Sj\u00f6gren's syndrome and is associated with systemic disease activity","volume":"19","author":"Mandl","year":"2017","unstructured":"51. Mandl T, Marsal J, Olsson P, Ohlsson B, Andr\u00e9asson K. Severe intestinal dysbiosis is prevalent in primary Sj\u00f6gren's syndrome and is associated with systemic disease activity. Arthritis Res Ther. 2017;19:237.","journal-title":"Arthritis Res Ther"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaut.2018.10.009","article-title":"Shared gut, but distinct oral microbiota composition in primary Sj\u00f6gren's syndrome and systemic lupus erythematosus","volume":"97","author":"van der Meulen","year":"2019","unstructured":"52. van der Meulen TA, Harmsen HJM, Vila AV, Kurilshikov A, Liefers SC, Zhernakova A, et al. Shared gut, but distinct oral microbiota composition in primary Sj\u00f6gren's syndrome and systemic lupus erythematosus. J Autoimmun. 2019;97:77-87.","journal-title":"J Autoimmun"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4161\/gmic.19320","article-title":"The role of gut microbiota in immune homeostasis and autoimmunity","volume":"3","author":"HJ","year":"2012","unstructured":"53. Wu HJ, Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes. 2012;3:4-14.","journal-title":"Gut Microbes"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3389\/fimmu.2017.00598","article-title":"Leaky Gut As a Danger Signal for Autoimmune Diseases","volume":"8","author":"Mu","year":"2017","unstructured":"54. Mu Q, Kirby J, Reilly CM, Luo XM. Leaky Gut As a Danger Signal for Autoimmune Diseases. Front Immunol. 2017;8:598.","journal-title":"Front Immunol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"689492","DOI":"10.1155\/2014\/689492","article-title":"The central role of the gut microbiota in chronic inflammatory diseases","volume":"2014","author":"Ferreira","year":"2014","unstructured":"55. Ferreira CM, Vieira AT, Vinolo MA, Oliveira FA, Curi R, Martins Fdos S. The central role of the gut microbiota in chronic inflammatory diseases. J Immunol Res. 2014;2014:689492.","journal-title":"J Immunol Res"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jaut.2018.06.004","article-title":"Protective role of commensal bacteria in Sj\u00f6gren Syndrome","volume":"93","author":"Zaheer","year":"2018","unstructured":"56. Zaheer M, Wang C, Bian F, Yu Z, Hernandez H, de Souza RG, et al. Protective role of commensal bacteria in Sj\u00f6gren Syndrome. J Autoimmun. 2018;93:45-56.","journal-title":"J Autoimmun"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"23561","DOI":"10.1038\/srep23561","article-title":"Altered Mucosal Microbiome Diversity and Disease Severity in Sj\u00f6gren Syndrome","volume":"6","author":"de Paiva","year":"2016","unstructured":"57. de Paiva CS, Jones DB, Stern ME, Bian F, Moore QL, Corbiere S, et al. Altered Mucosal Microbiome Diversity and Disease Severity in Sj\u00f6gren Syndrome. Sci Rep. 2016;6:23561.","journal-title":"Sci Rep"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.3390\/nu14102081","article-title":"The Microbiota-Gut-Brain Axis in Depression: The Potential Pathophysiological Mechanisms and Microbiota Combined Antidepression Effect","volume":"14","author":"Zhu","year":"2022","unstructured":"58. Zhu F, Tu H, Chen T. The Microbiota-Gut-Brain Axis in Depression: The Potential Pathophysiological Mechanisms and Microbiota Combined Antidepression Effect. Nutrients. 2022;14:2081.","journal-title":"Nutrients"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"59. Milic V, Grujic M, Barisic J, Marinkovic-Eric J, Duisin D, Cirkovic A, et al. Personality, depression and anxiety in primary Sjogren's syndrome - Association with sociodemographic factors and comorbidity. PLoS One. 2019;14:e0210466.","DOI":"10.1371\/journal.pone.0210466"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"173448","DOI":"10.1016\/j.pbb.2022.173448","article-title":"Depression-like behaviors in mouse model of Sj\u00f6gren's syndrome: A role of gut-microbiota-brain axis","volume":"219","author":"Pu","year":"2022","unstructured":"60. Pu Y, He Y, Zhao X, Zhang Q, Wen J, Hashimoto K, et al. Depression-like behaviors in mouse model of Sj\u00f6gren's syndrome: A role of gut-microbiota-brain axis. Pharmacol Biochem Behav. 2022;219:173448.","journal-title":"Pharmacol Biochem Behav"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3389\/fimmu.2019.01327","article-title":"Pulmonary Manifestations of Primary Sj\u00f6gren's Syndrome: Underlying Immunological Mechanisms, Clinical Presentation, and Management","volume":"10","author":"Gupta","year":"2019","unstructured":"61. Gupta S, Ferrada MA, Hasni SA. Pulmonary Manifestations of Primary Sj\u00f6gren's Syndrome: Underlying Immunological Mechanisms, Clinical Presentation, and Management. Front Immunol. 2019;10:1327.","journal-title":"Front Immunol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"200021","DOI":"10.1183\/16000617.0021-2020","article-title":"Lung complications of Sjogren syndrome","volume":"29","author":"Luppi","year":"2020","unstructured":"62. Luppi F, Sebastiani M, Sverzellati N, Cavazza A, Salvarani C, Manfredi A. Lung complications of Sjogren syndrome. Eur Respir Rev. 2020;29:200021.","journal-title":"Eur Respir Rev"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"63. Giles I, Isenberg D. Fatigue in primary Sj\u00f6gren's syndrome: is there a link with the fibromyalgia syndrome? Ann Rheum Dis. 2000;59:875-8.","DOI":"10.1136\/ard.59.11.875"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"64. Guo C, Che X, Briese T, Ranjan A, Allicock O, Yates RA, et al. Deficient butyrate-producing capacity in the gut microbiome is associated with bacterial network disturbances and fatigue symptoms in ME\/CFS. Cell Host Microbe. 2023;31:288-304.e288.","DOI":"10.1016\/j.chom.2023.01.004"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"65. Xiong R, Gunter C, Fleming E, Vernon SD, Bateman L, Unutmaz D, et al. Multi-'omics of gut microbiome-host interactions in short- and long-term myalgic encephalomyelitis\/chronic fatigue syndrome patients. Cell Host Microbe. 2023;31:273-87.e275.","DOI":"10.1016\/j.chom.2023.01.001"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"66. Zhou A, Lei Y, Tang L, Hu S, Yang M, Wu L, et al. Gut Microbiota: the Emerging Link to Lung Homeostasis and Disease. J Bacteriol. 2021;203:e00454-20.","DOI":"10.1128\/JB.00454-20"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"243723","DOI":"10.1155\/2015\/243723","article-title":"T Regulatory and T Helper 17 Cells in Primary Sj\u00f6gren's Syndrome: Facts and Perspectives","volume":"2015","author":"Alunno","year":"2015","unstructured":"67. Alunno A, Carubbi F, Bistoni O, Caterbi S, Bartoloni E, Mirabelli G, et al. T Regulatory and T Helper 17 Cells in Primary Sj\u00f6gren's Syndrome: Facts and Perspectives. Mediators Inflamm. 2015;2015:243723.","journal-title":"Mediators Inflamm"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"731947","DOI":"10.3389\/fimmu.2021.731947","article-title":"Regulatory T Cells in Autoimmunity and Cancer: A Duplicitous Lifestyle","volume":"12","author":"Hatzioannou","year":"2021","unstructured":"68. Hatzioannou A, Boumpas A, Papadopoulou M, Papafragkos I, Varveri A, Alissafi T, et al. Regulatory T Cells in Autoimmunity and Cancer: A Duplicitous Lifestyle. Front Immunol. 2021;12:731947.","journal-title":"Front Immunol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/ibd.21709","article-title":"Consumption of probiotics increases the effect of regulatory T cells in transfer colitis","volume":"18","author":"Petersen","year":"2012","unstructured":"69. Petersen ER, Claesson MH, Schmidt EG, Jensen SS, Ravn P, Olsen J, et al. Consumption of probiotics increases the effect of regulatory T cells in transfer colitis. Inflamm Bowel Dis. 2012;18:131-42.","journal-title":"Inflamm Bowel Dis"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/1756283X15607414","article-title":"Fecal microbiota transplantation: in perspective","volume":"9","author":"Gupta","year":"2016","unstructured":"70. Gupta S, Allen-Vercoe E, Petrof EO. Fecal microbiota transplantation: in perspective. Therap Adv Gastroenterol. 2016;9:229-39.","journal-title":"Therap Adv Gastroenterol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1097\/CM9.0000000000002339","article-title":"Encyclopedia of fecal microbiota transplantation: a review of effectiveness in the treatment of 85 diseases","volume":"135","author":"Wang","year":"2022","unstructured":"71. Wang Y, Zhang S, Borody TJ, Zhang F. Encyclopedia of fecal microbiota transplantation: a review of effectiveness in the treatment of 85 diseases. Chin Med J (Engl). 2022;135:1927-39.","journal-title":"Chin Med J (Engl)"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ajo.2021.06.022","article-title":"Fecal Microbial Transplant in Individuals With Immune-Mediated Dry Eye","volume":"233","author":"Watane","year":"2022","unstructured":"72. Watane A, Cavuoto KM, Rojas M, Dermer H, Day JO, Banerjee S, et al. Fecal Microbial Transplant in Individuals With Immune-Mediated Dry Eye. Am J Ophthalmol. 2022;233:90-100.","journal-title":"Am J Ophthalmol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41575-019-0173-3","article-title":"Probiotics and prebiotics in intestinal health and disease: from biology to the clinic","volume":"16","author":"Sanders","year":"2019","unstructured":"73. Sanders ME, Merenstein DJ, Reid G, Gibson GR, Rastall RA. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat Rev Gastroenterol Hepatol. 2019;16:605-16.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3389\/fmicb.2015.01050","article-title":"Human microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approaches","volume":"6","author":"Beliz\u00e1rio JE","year":"2015","unstructured":"74. Beliz\u00e1rio JE, Napolitano M. Human microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approaches. Front Microbiol. 2015;6:1050.","journal-title":"Front Microbiol"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"75. Liu Y, Tran DQ, Rhoads JM. Probiotics in Disease Prevention and Treatment. J Clin Pharmacol. 2018;58(Suppl 10):S164-79.","DOI":"10.1002\/jcph.1121"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/10408398.2017.1379469","article-title":"Human microbiota in aging and infection: A review","volume":"59","author":"Stavropoulou","year":"2019","unstructured":"76. Stavropoulou E, Bezirtzoglou E. Human microbiota in aging and infection: A review. Crit Rev Food Sci Nutr. 2019;59:537-45.","journal-title":"Crit Rev Food Sci Nutr"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"77. West CE, Renz H, Jenmalm MC, Kozyrskyj AL, Allen KJ, Vuillermin P, et al. The gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapies. J Allergy Clin Immunol. 2015;135:3-13; quiz 14.","DOI":"10.1016\/j.jaci.2014.11.012"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.autrev.2016.01.002","article-title":"Induction of regulatory T cells: A role for probiotics and prebiotics to suppress autoimmunity","volume":"15","author":"Dwivedi","year":"2016","unstructured":"78. Dwivedi M, Kumar P, Laddha NC, Kemp EH. Induction of regulatory T cells: A role for probiotics and prebiotics to suppress autoimmunity. Autoimmun Rev. 2016;15:379-92.","journal-title":"Autoimmun Rev"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/ibd.20525","article-title":"Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases","volume":"14","author":"Vanderpool","year":"2008","unstructured":"79. Vanderpool C, Yan F, Polk DB. Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases. Inflamm Bowel Dis. 2008;14:1585-96.","journal-title":"Inflamm Bowel Dis"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/MOG.0b013e32834baa4d","article-title":"Probiotics and immune health","volume":"27","author":"Yan","year":"2011","unstructured":"80. Yan F, Polk DB. Probiotics and immune health. Curr Opin Gastroenterol. 2011;27:496-501.","journal-title":"Curr Opin Gastroenterol"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"81. van Baarlen P, Troost F, van der Meer C, Hooiveld G, Boekschoten M, Brummer RJ, et al. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proc Natl Acad Sci U S A. 2011;108(Suppl 1):4562-9.","DOI":"10.1073\/pnas.1000079107"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2353\/ajpath.2008.080246","article-title":"Foxp3+ T-regulatory cells in Sjogren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors","volume":"173","author":"Christodoulou","year":"2008","unstructured":"82. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos NM, Moutsopoulos HM. Foxp3+ T-regulatory cells in Sjogren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors. Am J Pathol. 2008;173:1389-96.","journal-title":"Am J Pathol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1073\/pnas.0904055107","article-title":"Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders","volume":"107","author":"Kwon","year":"2010","unstructured":"83. Kwon HK, Lee CG, So JS, Chae CS, Hwang JS, Sahoo A, et al. Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. Proc Natl Acad Sci U S A. 2010;107:2159-64.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"742","DOI":"10.3748\/wjg.v19.i5.742","article-title":"Probiotics increase T regulatory cells and reduce severity of experimental colitis in mice","volume":"19","author":"Zhao","year":"2013","unstructured":"84. Zhao HM, Huang XY, Zuo ZQ, Pan QH, Ao MY, Zhou F, et al. Probiotics increase T regulatory cells and reduce severity of experimental colitis in mice. World J Gastroenterol. 2013;19:742-9.","journal-title":"World J Gastroenterol"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/1756-185X.12888","article-title":"Clinical and metabolic response to probiotic supplementation in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial","volume":"19","author":"Zamani","year":"2016","unstructured":"85. Zamani B, Golkar HR, Farshbaf S, Emadi-Baygi M, Tajabadi-Ebrahimi M, Jafari P, et al. Clinical and metabolic response to probiotic supplementation in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Int J Rheum Dis. 2016;19:869-79.","journal-title":"Int J Rheum Dis"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"86. Alipour B, Homayouni-Rad A, Vaghef-Mehrabany E, Sharif SK, Vaghef-Mehrabany L, Asghari-Jafarabadi M, et al. Effects of Lactobacillus casei supplementation on disease activity and inflammatory cytokines in rheumatoid arthritis patients: a randomized double-blind clinical trial. Int J Rheum Dis. 2014;17:519-27.","DOI":"10.1111\/1756-185X.12333"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"711788","DOI":"10.3389\/fphar.2021.711788","article-title":"Probiotic Supplementation for Rheumatoid Arthritis: A Promising Adjuvant Therapy in the Gut Microbiome Era","volume":"12","author":"Ferro","year":"2021","unstructured":"87. Ferro M, Charneca S, Dourado E, Guerreiro CS, Fonseca JE. Probiotic Supplementation for Rheumatoid Arthritis: A Promising Adjuvant Therapy in the Gut Microbiome Era. Front Pharmacol. 2021;12:711788.","journal-title":"Front Pharmacol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-018-0620-2","article-title":"The human gut microbiome in early-onset type 1 diabetes from the TEDDY study","volume":"562","author":"Vatanen","year":"2018","unstructured":"88. Vatanen T, Franzosa EA, Schwager R, Tripathi S, Arthur TD, Vehik K, et al. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. Nature. 2018;562:589-94.","journal-title":"Nature"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1001\/jamapediatrics.2015.2757","article-title":"Association of Early Exposure of Probiotics and Islet Autoimmunity in the TEDDY Study","volume":"170","author":"Uusitalo","year":"2016","unstructured":"89. Uusitalo U, Liu X, Yang J, Aronsson CA, Hummel S, Butterworth M, et al. Association of Early Exposure of Probiotics and Islet Autoimmunity in the TEDDY Study. JAMA Pediatr. 2016;170:20-8.","journal-title":"JAMA Pediatr"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3389\/fimmu.2017.00655","article-title":"2 Modulates the Host Immune Responses: A Double-Blind, Randomized Trial in Healthy Adults","volume":"8","author":"Marcial","year":"2017","unstructured":"90. Marcial GE, Ford AL, Haller MJ, Gezan SA, Harrison NA, Cai D, et al. Lactobacillus johnsonii N6.2 Modulates the Host Immune Responses: A Double-Blind, Randomized Trial in Healthy Adults. Front Immunol. 2017;8:655.","journal-title":"Front Immunol"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1210\/en.2010-0538","article-title":"Dreams for type 1 diabetes: shutting off autoimmunity and stimulating beta-cell regeneration","volume":"151","author":"Weir","year":"2010","unstructured":"91. Weir GC, Bonner-Weir S. Dreams for type 1 diabetes: shutting off autoimmunity and stimulating beta-cell regeneration. Endocrinology. 2010;151:2971-3.","journal-title":"Endocrinology"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"25088","DOI":"10.1074\/jbc.M113.452516","article-title":"Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion","volume":"288","author":"Yadav","year":"2013","unstructured":"92. Yadav H, Lee JH, Lloyd J, Walter P, Rane SG. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem. 2013;288:25088-97.","journal-title":"J Biol Chem"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"9973","DOI":"10.1073\/pnas.1508740112","article-title":"Microbiota regulates type 1 diabetes through Toll-like receptors","volume":"112","author":"Burrows","year":"2015","unstructured":"93. Burrows MP, Volchkov P, Kobayashi KS, Chervonsky AV. Microbiota regulates type 1 diabetes through Toll-like receptors. Proc Natl Acad Sci U S A. 2015;112:9973-7.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"94. Groele L, Szajewska H, Szypowska A. Effects of Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 on beta-cell function in children with newly diagnosed type 1 diabetes: protocol of a randomised controlled trial. BMJ Open. 2017;7:e017178.","DOI":"10.1136\/bmjopen-2017-017178"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1039\/D0FO03203D","article-title":"Efficacy of probiotics in multiple sclerosis: a systematic review of preclinical trials and meta-analysis of randomized controlled trials","volume":"12","author":"Jiang","year":"2021","unstructured":"95. Jiang J, Chu C, Wu C, Wang C, Zhang C, Li T, et al. Efficacy of probiotics in multiple sclerosis: a systematic review of preclinical trials and meta-analysis of randomized controlled trials. Food Funct. 2021;12:2354-77.","journal-title":"Food Funct"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"901846","DOI":"10.3389\/fnins.2022.901846","article-title":"Probiotic supplementation and systemic inflammation in relapsing-remitting multiple sclerosis: A randomized, double-blind, placebo-controlled trial","volume":"16","author":"Rahimlou","year":"2022","unstructured":"96. Rahimlou M, Nematollahi S, Husain D, Banaei-Jahromi N, Majdinasab N, Hosseini SA. Probiotic supplementation and systemic inflammation in relapsing-remitting multiple sclerosis: A randomized, double-blind, placebo-controlled trial. Front Neurosci. 2022;16:901846.","journal-title":"Front Neurosci"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1039\/D0FO02984J","article-title":"Lactobacillus plantarum and Bifidobacterium bifidum alleviate dry eye in mice with exorbital lacrimal gland excision by modulating gut inflammation and microbiota","volume":"12","author":"Yun","year":"2021","unstructured":"97. Yun SW, Son YH, Lee DY, Shin YJ, Han MJ, Kim DH. Lactobacillus plantarum and Bifidobacterium bifidum alleviate dry eye in mice with exorbital lacrimal gland excision by modulating gut inflammation and microbiota. Food Funct. 2021;12:2489-97.","journal-title":"Food Funct"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"98. Moon J, Ryu JS, Kim JY, Im SH, Kim MK. Effect of IRT5 probiotics on dry eye in the experimental dry eye mouse model. PLoS One. 2020;15:e0243176.","DOI":"10.1371\/journal.pone.0243176"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.3390\/jcm11164889","article-title":"The Impact of Probiotics and Prebiotics on Dry Eye Disease Signs and Symptoms","volume":"11","author":"Tavakoli","year":"2022","unstructured":"99. Tavakoli A, Markoulli M, Papas E, Flanagan J. The Impact of Probiotics and Prebiotics on Dry Eye Disease Signs and Symptoms. J Clin Med. 2022;11:4889.","journal-title":"J Clin Med"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00296-020-04558-9","article-title":"Probiotics as a prophylaxis to prevent oral candidiasis in patients with Sjogren's syndrome: a double-blinded, placebo-controlled, randomized trial","volume":"40","author":"Kamal","year":"2020","unstructured":"100. Kamal Y, Kandil M, Eissa M, Yousef R, Elsaadany B. Probiotics as a prophylaxis to prevent oral candidiasis in patients with Sjogren's syndrome: a double-blinded, placebo-controlled, randomized trial. Rheumatol Int. 2020;40:873-9.","journal-title":"Rheumatol Int"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"101. Brignardello-Petersen R. Small trial with short duration does not provide evidence that probiotics reduce the risk of developing oral candidiasis in patients with Sj\u00f6gren syndrome. J Am Dent Assoc. 2020;151:e92.","DOI":"10.1016\/j.adaj.2020.06.028"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"102. Meijerink M, van Hemert S, Taverne N, Wels M, de Vos P, Bron PA, et al. Identification of genetic loci in Lactobacillus plantarum that modulate the immune response of dendritic cells using comparative genome hybridization. PLoS One. 2010;5:e10632.","DOI":"10.1371\/journal.pone.0010632"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"881","DOI":"10.15252\/embj.201490296","article-title":"SIGNR3-dependent immune regulation by Lactobacillus acidophilus surface layer protein A in colitis","volume":"34","author":"Lightfoot","year":"2015","unstructured":"103. Lightfoot YL, Selle K, Yang T, Goh YJ, Sahay B, Zadeh M, et al. SIGNR3-dependent immune regulation by Lactobacillus acidophilus surface layer protein A in colitis. Embo J. 2015;34:881-95.","journal-title":"Embo J"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41579-019-0255-9","article-title":"Common principles and best practices for engineering microbiomes","volume":"17","author":"Lawson","year":"2019","unstructured":"104. Lawson CE, Harcombe WR, Hatzenpichler R, Lindemann SR, L\u00f6ffler FE, O'Malley MA, et al. Common principles and best practices for engineering microbiomes. Nat Rev Microbiol. 2019;17:725-41.","journal-title":"Nat Rev Microbiol"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/s41467-020-15508-1","article-title":"Developing a new class of engineered live bacterial therapeutics to treat human diseases","volume":"11","author":"Charbonneau","year":"2020","unstructured":"105. Charbonneau MR, Isabella VM, Li N, Kurtz CB. Developing a new class of engineered live bacterial therapeutics to treat human diseases. Nat Commun. 2020;11:1738.","journal-title":"Nat Commun"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/nbt840","article-title":"Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10","volume":"21","author":"Steidler","year":"2003","unstructured":"106. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol. 2003;21:785-789.","journal-title":"Nat Biotechnol"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.cgh.2006.03.028","article-title":"A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease","volume":"4","author":"Braat","year":"2006","unstructured":"107. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:754-9.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.4049\/jimmunol.1100530","article-title":"Segregated regulatory CD39+CD4+ T cell function: TGF-\u03b2-producing Foxp3\u2212 and IL-10-producing Foxp3+ cells are interdependent for protection against collagen-induced arthritis","volume":"187","author":"Kochetkova","year":"2011","unstructured":"108. Kochetkova I, Thornburg T, Callis G, Pascual DW. Segregated regulatory CD39+CD4+ T cell function: TGF-\u03b2-producing Foxp3\u2212 and IL-10-producing Foxp3+ cells are interdependent for protection against collagen-induced arthritis. J Immunol. 2011;187:4654-66.","journal-title":"J Immunol"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"804","DOI":"10.4049\/jimmunol.1302018","article-title":"Oral Escherichia coli colonization factor antigen I fimbriae ameliorate arthritis via IL-35, not IL-27","volume":"192","author":"Kochetkova","year":"2014","unstructured":"109. Kochetkova I, Thornburg T, Callis G, Holderness K, Maddaloni M, Pascual DW. Oral Escherichia coli colonization factor antigen I fimbriae ameliorate arthritis via IL-35, not IL-27. J Immunol. 2014;192:804-16.","journal-title":"J Immunol"},{"key":"ref109","doi-asserted-by":"publisher","unstructured":"110. Maddaloni M, Kochetkova I, Jun S, Callis G, Thornburg T, Pascual DW. Milk-based nutraceutical for treating autoimmune arthritis via the stimulation of IL-10- and TGF-beta-producing CD39+ regulatory T cells. PLoS One. 2015;10:e0117825.","DOI":"10.1371\/journal.pone.0117825"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.4049\/jimmunol.178.3.1791","article-title":"Regulatory T cell vaccination without autoantigen protects against experimental autoimmune encephalomyelitis","volume":"178","author":"Ochoa-Reparaz","year":"2007","unstructured":"111. Ochoa-Reparaz J, Riccardi C, Rynda A, Jun S, Callis G, Pascual DW. Regulatory T cell vaccination without autoantigen protects against experimental autoimmune encephalomyelitis. J Immunol. 2007;178:1791-9.","journal-title":"J Immunol"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2174\/187153007781662549","article-title":"Tolerance in the absence of autoantigen","volume":"7","author":"Pascual","year":"2007","unstructured":"112. Pascual DW, Ochoa-Reparaz J, Rynda A, Yang X. Tolerance in the absence of autoantigen. Endocr Metab Immune Disord Drug Targets. 2007;7:203-10.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"6156","DOI":"10.1038\/s41598-020-62881-4","article-title":"Oral therapy with colonization factor antigen I prevents development of type 1 diabetes in Non-obese Diabetic mice","volume":"10","author":"Nelson","year":"2020","unstructured":"113. Nelson AS, Maddaloni M, Abbott JR, Hoffman C, Akgul A, Ohland C, et al. Oral therapy with colonization factor antigen I prevents development of type 1 diabetes in Non-obese Diabetic mice. Sci Rep. 2020;10:6156.","journal-title":"Sci Rep"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13075-021-02475-1","article-title":"coli colonization factor antigen 1 retains salivary flow in a genetic model of Sj\u00f6gren's syndrome","volume":"23","author":"Akgul","year":"2021","unstructured":"114. Akgul A, Maddaloni M, Jun SM, Nelson AS, Odreman VA, Hoffman C, et al. Stimulation of regulatory T cells with Lactococcus lactis expressing enterotoxigenic E. coli colonization factor antigen 1 retains salivary flow in a genetic model of Sj\u00f6gren's syndrome. Arthritis Res Ther. 2021;23:99.","journal-title":"Arthritis Res Ther"},{"key":"ref114","unstructured":"115. A Phase 2a Study to Evaluate the Safety T, Pharmacodynamics and efficacy of AG011 in ulcerative colitis, ClinicalTrials.gov Identifier: NCT00729872. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00729872. Accessed 2023 May 2."},{"key":"ref115","unstructured":"116. Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day, ClinicalTrials.gov Identifier: NCT03234465. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03234465. Accessed 2023 May 2."},{"key":"ref116","unstructured":"117. A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D). ClinicalTrials.gov Identifier: NCT03751007. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03751007. Accessed 2023 May 2"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jconrel.2020.06.016","article-title":"Challenges & opportunities for phage-based in situ microbiome engineering in the gut","volume":"326","author":"Voorhees","year":"2020","unstructured":"118. Voorhees PJ, Cruz-Teran C, Edelstein J, Lai SK. Challenges & opportunities for phage-based in situ microbiome engineering in the gut. J Control Release. 2020;326:106-19.","journal-title":"J Control Release"},{"issue":"9","key":"ref118","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.3390\/microorganisms8091420","article-title":"Phage Therapy in Gastrointestinal Diseases","volume":"8","author":"Guti\u00e9rrez","year":"2020","unstructured":"119. Guti\u00e9rrez B, Domingo-Calap P. Phage Therapy in Gastrointestinal Diseases. Microorganisms. 2020;8(9):1420.","journal-title":"Microorganisms"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"3612015","DOI":"10.1155\/2017\/3612015","article-title":"In Vivo Studies on the Influence of Bacteriophage Preparations on the Autoimmune Inflammatory Process","volume":"2017","author":"Mi\u0119dzybrodzki","year":"2017","unstructured":"120. Mi\u0119dzybrodzki R, Borysowski J, K\u0142ak M, Jo\u0144czyk-Matysiak E, Obmi\u0144ska-Mrukowicz B, Suszko-Paw\u0142owska A, et al. In Vivo Studies on the Influence of Bacteriophage Preparations on the Autoimmune Inflammatory Process. Biomed Res Int. 2017;2017:3612015.","journal-title":"Biomed Res Int"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"874021","DOI":"10.3389\/fimmu.2022.874021","article-title":"Comprehensive Analysis of the Relationships Between the Gut Microbiota and Fecal Metabolome in Individuals With Primary Sjogren's Syndrome by 16S rRNA Sequencing and LC-MS-Based Metabolomics","volume":"13","author":"Yang","year":"2022","unstructured":"121. Yang L, Xiang Z, Zou J, Zhang Y, Ni Y, Yang J. Comprehensive Analysis of the Relationships Between the Gut Microbiota and Fecal Metabolome in Individuals With Primary Sjogren's Syndrome by 16S rRNA Sequencing and LC-MS-Based Metabolomics. Front Immunol. 2022;13:874021.","journal-title":"Front Immunol"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"860586","DOI":"10.3389\/fimmu.2022.860586","article-title":"Lipid Metabolism: Immune Regulation and Therapeutic Prospectives in Systemic Lupus Erythematosus","volume":"13","author":"Sun","year":"2022","unstructured":"122. Sun W, Li P, Cai J, Ma J, Zhang X, Song Y, et al. Lipid Metabolism: Immune Regulation and Therapeutic Prospectives in Systemic Lupus Erythematosus. Front Immunol. 2022;13:860586.","journal-title":"Front Immunol"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"943241","DOI":"10.3389\/fimmu.2022.943241","article-title":"Gut microbiota in systemic lupus erythematosus patients and lupus mouse model: a cross species comparative analysis for biomarker discovery","volume":"13","author":"Toumi","year":"2022","unstructured":"123. Toumi E, Goutorbe B, Plauzolles A, Bonnet M, Mezouar S, Militello M, et al. Gut microbiota in systemic lupus erythematosus patients and lupus mouse model: a cross species comparative analysis for biomarker discovery. Front Immunol. 2022;13:943241.","journal-title":"Front Immunol"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"908174","DOI":"10.3389\/fimmu.2022.908174","article-title":"Microbiota-Derived Propionate Modulates Megakaryopoiesis and Platelet Function","volume":"13","author":"D\u00fcrholz","year":"2022","unstructured":"124. D\u00fcrholz K, Schmid E, Frech M, Azizov V, Otterbein N, Lucas S,et al. Microbiota-Derived Propionate Modulates Megakaryopoiesis and Platelet Function. Front Immunol. 2022;13:908174.","journal-title":"Front Immunol"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"102611","DOI":"10.1016\/j.jaut.2021.102611","article-title":"Short-chain fatty acid butyrate induces IL-10-producing B cells by regulating circadian-clock-related genes to ameliorate Sj\u00f6gren's syndrome","volume":"119","author":"Kim","year":"2021","unstructured":"125. Kim DS, Woo JS, Min HK, Choi JW, Moon JH, Park MJ,et al. Short-chain fatty acid butyrate induces IL-10-producing B cells by regulating circadian-clock-related genes to ameliorate Sj\u00f6gren's syndrome. J Autoimmun. 2021;119:102611.","journal-title":"J Autoimmun"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"4512","DOI":"10.1038\/s41598-022-08442-3","article-title":"Gut-derived butyrate suppresses ocular surface inflammation","volume":"12","author":"Schaefer","year":"2022","unstructured":"126. Schaefer L, Hernandez H, Coats RA, Yu Z, Pflugfelder SC, Britton RA, et al. Gut-derived butyrate suppresses ocular surface inflammation. Sci Rep. 2022;12:4512","journal-title":"Sci Rep"}],"container-title":["Advances in Geriatric Medicine and Research"],"original-title":[],"link":[{"URL":"https:\/\/agmr.hapres.com\/UpLoad\/PdfFile\/AGMR_1526.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T00:52:29Z","timestamp":1683939149000},"score":1,"resource":{"primary":{"URL":"https:\/\/agmr.hapres.com\/htmls\/AGMR_1526_Detail.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":126,"URL":"https:\/\/doi.org\/10.20900\/agmr20230004","relation":{},"ISSN":["2632-9921"],"issn-type":[{"value":"2632-9921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]}}}